Pfizer 2014 Annual Report Download

Download and view the complete annual report

Please find the complete 2014 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

PFIZER ANNUAL REVIEW 2014 www.pzer.com/annual 1
ANNUAL REVIEW 2014
Q&A WITH PFIZER
Q&A WITH PFIZER
Q: WHY DO YOU
WORK AT PFIZER?
LAURIE OLSON
STRATEGY, PORTFOLIO,
AND COMMERCIAL OPERATIONS
Q: WHY DO PEOPLE
SAY MEDICINES ARE
SO EXPENSIVE?
JUSTIN MCCARTHY
GLOBAL POLICY &
INTERNATIONAL PUBLIC AFFAIRS
Q: WHAT PROGRAMS
DOES PFIZER HAVE TO
HELP PEOPLE ACCESS
OUR MEDICINES GLOBALLY?
CAROLINE ROAN
CORPORATE RESPONSIBILITY
Homepage > Q&A with Pzer

Table of contents

  • Page 1
    ...Q: WHY DO PEOPLE SAY MEDICINES ARE SO EXPENSIVE? JUSTIN MCCARTHY GLOBAL POLICY & INTERNATIONAL PUBLIC AFFAIRS Q: WHAT PROGRAMS DOES PFIZER HAVE TO HELP PEOPLE ACCESS OUR MEDICINES GLOBALLY? CAROLINE ROAN CORPORATE RESPONSIBILITY PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Homepage > Q&A with...

  • Page 2
    ... WALDEN PFIZER GLOBAL SUPPLY Q: HOW DOES PFIZER CHOOSE WHAT MEDICINES TO FOCUS R&D EFFORTS ON? JULIE SCHIFFMAN PORTFOLIO & DECISION ANALYSIS Q: WHY IS IT SO DIFFICULT TO FIND A CURE FOR CANCER? JOHN LIN WORLDWIDE RESEARCH AND DEVELOPMENT PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Homepage...

  • Page 3
    ... help and support they need. These women are warriors, and I look at them in awe." LILLIE SHOCKNEY, RN ADMINISTRATIVE DIRECTOR JOHNS HOPKINS BREAST CENTER and a 22-year breast cancer survivor IBRANCE® (PALBOCICLIB) APPROVED BY THE U.S. FDA On February 3, 2015, the U.S. Food and Drug Administration...

  • Page 4
    ... Institutes of Health and industry, designed to bridge the gap between early scientific discovery and its translation into new medicines. With four locations in the biomedical research hubs of Boston, New York, San Diego and San Francisco, CTI's open innovation model puts Pfizer scientists in the...

  • Page 5
    ...with organizations of older people, the curriculum reform and support to improve health information management will be undertaken together with the Ministry of Health and Social Welfare at various levels. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Homepage > Discoveries for Healthier Lives 5

  • Page 6
    ... of Serogroup B Meningococcal Disease, United States. Advisory Committee on Immunization Practices, October 30, 2014. http://www.cdc.gov/vaccines/ acip/meetings/downloads/slides-2014-10/mening-02-MacNeil.pdf. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Homepage > Discoveries for Healthier...

  • Page 7
    ... not being managed effectively with warfarin." CHRISTOPHER GRANGER, M.D. PROFESSOR OF MEDICINE DIRECTOR, CARDIAC CARE UNIT DUKE UNIVERSITY MEDICAL CENTER ELIQUIS® PROVIDING AN ALTERNATIVE TO WARFARIN Eliquis (apixaban) is a novel oral anticoagulant (NOAC) jointly developed by Pfizer and Bristol...

  • Page 8
    ... service delivery. Fellows transfer their pharmaceutical and business expertise in ways that promote access, quality and efficiency of health care. In exchange, Fellows return with experience and relationships that help inform their ability to have an impact on pressing health concerns. The Global...

  • Page 9
    ... on a multi-year journey, and during 2014 we achieved a number of important milestones despite a slow-growth global economy and the losses of exclusivity and co-promotion rights to some of our major medicines. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual CEO Letter > Letter to Stakeholders 9

  • Page 10
    ...-alone treatment and in combination with Merck's Januvia® and the widely used diabetes drug metformin. While ertugliflozin is not the first to market, we are developing it with the goal of "best-in-class." PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual CEO Letter > Letter to Stakeholders 10

  • Page 11
    ... Build and sustain a culture where colleagues view themselves as owners, generating new ideas, dealing with problems in a straightforward way, investing in open and candid conversations and working as teammates on challenges and opportunities. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual CEO...

  • Page 12
    ... disease. In 2014, we helped form the Rare Disease Consortium, with agreements between certain U.K. universities and academic health centers and Pfizer, bringing together a range of skills and technologies needed to speed up the flow of potential new therapies. We also expanded Pfizer's rare disease...

  • Page 13
    .../AIDS. Along with new vaccines, we continue to invest in clinical studies to expand the value of our marketed portfolio, including Prevnar 13,® our largest-selling vaccine. Early in 2014, we announced that a landmark study called CAPiTA (for Community-Acquired Pneumonia Immunization Trial in Adults...

  • Page 14
    ... our 2014 Annual Report on Form 10-K, a copy of which is on our company website, www.pfizer.com. We achieved these strong financial results while simultaneously operating in a new commercial structure consisting of two distinct businesses: an Innovative Products business and an Established Products...

  • Page 15
    ..., to expand access to Pfizer's long-acting contraceptive, Sayana® Press, for women most in need in 69 of the world's poorest countries. This collaboration will help advance progress and support global efforts to increase access to voluntary family planning information, services and contraceptives...

  • Page 16
    ... by Pfizer's Chief Medical Officer, is bearing results. Some 88% of those exposed to this outreach emerged with a positive impression of Pfizer. The benefits of the innovative medicines and therapies coming from our research labs make their way to patients through Pfizer Global Supply's industry...

  • Page 17
    ... of sales as a percentage of adjusted revenues, adjusted selling, informational and administrative expenses, adjusted R&D expenses, adjusted (income)/deductions, effective tax rate on adjusted income and adjusted diluted earnings per share (EPS) and GAAP reported diluted EPS. See the Company's 2014...

  • Page 18
    ... - diluted Number of common shares outstanding Total assets Total Long-term obligations(a),(c) Total Pfizer Inc. shareholders' equity Shareholders' equity per common share Net cash provided by operating activities Property, plant and equipment additions Purchases of common stock Cash dividends paid...

  • Page 19
    ... OF TOP 20 GLOBAL BURDENS OF DISEASE ADDRESSED BY PRODUCTS AND PIPELINE2 68 NUMBER OF EMERGING MARKETS IN WHICH PFIZER HAS IMPLEMENTED INTRA-COUNTRY TIERED PRICING3 COLLEAGUES 0.52 INJURIES PER 100 COLLEAGUES TOTAL INJURY RATE TOTAL INJURY RATE IN 2014 WAS 1% LOWER THAN IN 2013. ENVIRONMENTAL...

  • Page 20
    ...$7.2 EFFECTIVE TAX RATE ON ADJUSTED INCOME 2 2014 GUIDANCE 3 2014 GUIDANCE 3 APPROX. ($400) OF INCOME 2015 GUIDANCE 4 APPROX. 27.0% 2015 GUIDANCE 4 APPROX. ($500) OF INCOME 2014 ACTUAL APPROX. 25.0% 2014 ACTUAL ($567) OF INCOME PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual 26.5% CEO Letter...

  • Page 21
    ... September 28, 2014. Revenues and cost of sales from the transitional manufacturing and supply agreements with Zoetis were excluded from the applicable Adjusted components of the financial guidance. Reported and Adjusted Diluted EPS(2) guidance assumed diluted weighted-average shares outstanding of...

  • Page 22
    ... (2) Compensation Committee (3) Corporate Governance Committee (4) Regulatory and Compliance Committee (5) Science and Technology Committee (6) Lead Independent Director *Will retire as a Board Member effective as of April 2015 Annual Meeting PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual CEO...

  • Page 23
    ... Supply Laurie Olson Executive Vice President, Strategy, Portfolio and Commercial Operations Sally Susman Executive Vice President, Corporate Affairs John Young Group President, Global Established Pharma Business PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual CEO Letter > Executive Leadership...

  • Page 24
    ... commercial businesses. GLOBAL INNOVATIVE PHARMA BUSINESS GLOBAL VACCINES, ONCOLOGY AND CONSUMER HEALTHCARE BUSINESS GLOBAL ESTABLISHED PHARMA BUSINESS WORLDWIDE RESEARCH & DEVELOPMENT PFIZER GLOBAL SUPPLY ENABLING FUNCTIONS PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Business > How...

  • Page 25
    ...and women's/men's health and include leading brands, such as Xeljanz,® Eliquis® and Lyrica® (U.S. and Japan). GIP has a robust pipeline of medicines in inflammation, cardiovascular / metabolic disease, pain and rare diseases. GLOBAL ESTABLISHED PHARMA BUSINESS Global Established Pharma (GEP) is...

  • Page 26
    ... Therapy designation and Priority Review programs. Pfizer Consumer Healthcare helps consumers around the world take control of their health and well-being with science-based, differentiated self-care solutions. We are ranked fifth globally among multinational, branded consumer health care companies...

  • Page 27
    ... been developed to ensure that the information we share with patients is scientifically sound, balanced, easy to understand and helpful in encouraging them to consult with a health care professional. Read more about our Direct-to-Consumer Advertising here. HUMAN RIGHTS Pfizer supports the Universal...

  • Page 28
    ... innovation. We want every colleague to see and appreciate the opportunities presented by change, and then try something new, think differently and strive for the best business outcome." TANYA CLEMONS SENIOR VICE PRESIDENT, CHIEF TALENT OFFICER & WORLDWIDE RESEARCH AND DEVELOPMENT HUMAN RESOURCES...

  • Page 29
    ...YOU WORK AT PFIZER? LAURIE OLSON STRATEGY, PORTFOLIO, AND COMMERCIAL OPERATIONS On our second annual OWNIT! day, colleagues attended a workshop that introduced participants to a Thriving in Change framework and tips for managing change. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Business...

  • Page 30
    ... to a variety of developmental activities, including action learning immersion projects with an NGO partner in an emerging market. These senior leaders were actively supported by our CEO and his leadership team. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Business > Our Colleagues 30

  • Page 31
    ... team has built a robust and effective talent brand that reaches career seekers in all regions of the world. When You're One of the Best, the Best Talent Finds You • • Named to the Hay Group's prestigious 2014 Best Companies for Leadership Named a top employer in South Africa for 2015...

  • Page 32
    ANNUAL REVIEW 2014 OUR COLLEAGUES DIVERSITY MATTERS: DEVELOPING DIVERSE TALENT TO HELP DRIVE BUSINESS RESULTS Building a diverse workforce and an inclusive workplace expands access to innovative ideas and global markets and helps us to earn respect from society. Throughout our enterprise we have ...

  • Page 33
    ... and productive. Our health and safety program directly connects with our ownership culture, engaging colleagues in work place safety. The program is well-established, built on risk assessment and control, and driven by Pfizer leaders. We see value in doing more to enhance employee health, and...

  • Page 34
    ...of medicines that meet exacting standards for quality and effectiveness. 175+ MARKETS 130 DISTRIBUTION NETWORK SITES 55 INTERNAL MANUFACTURING SITES 200+ SUPPLY PARTNERS 600+ MAJOR PRODUCT GROUPS PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Business > Manufacturing and Supply Chain 34

  • Page 35
    ... on how quality fosters trust and ensures patient safety MIN JEREMY HUA COQA MANAGER QUALITY CHINA Q: HOW CAN I TRUST THE QUALITY OF PFIZER MEDICINES AND VACCINES? GEORGE WALDEN PFIZER GLOBAL SUPPLY PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Business > Manufacturing and Supply Chain 35

  • Page 36
    ... trade compliance and trade management. It also supports business continuity and proactive issue identification and resolution. Pfizer is an industry-recognized leader in supply chain security. Our dedicated security program encompasses every part of the manufacturing and delivery process, starting...

  • Page 37
    ...of our business and the communities in which we operate. To that end, our external supply team oversees efforts to help ensure that our chemical and biological product suppliers manage environment, health and safety risks. Our Environmental Health and Safety (EHS) team performs riskbased reviews of...

  • Page 38
    ...-entry share ownership Direct deposit of dividends Patients, customers and health care professionals who have questions about any of our products should call 1-800-438-1985. Patients in the U.S. who need help getting access to their Pfizer medicines should contact Pfizer RxPathways.® The program...

  • Page 39
    ..., with a goal of delivering a sustainable flow of important new medicines and vaccines, year after year. Q: WHY IS IT SO DIFFICULT TO FIND A CURE FOR CANCER? JOHN LIN WORLDWIDE RESEARCH AND DEVELOPMENT PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Science > Research and Development 39

  • Page 40
    ... innovate and succeed on a difficult mechanism where many others had failed, and thereby potentially help patients with Parkinson's disease live a better life." DAVID GRAY NEUROSCIENCE RESEARCH UNIT PROJECT LEAD FOR THE D1 PARTIAL AGONIST PROGRAM PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual...

  • Page 41
    ... REVIEW 2014 RESEARCH AND DEVELOPMENT OUR THERAPEUTIC AREAS OF FOCUS In addition, we pursue R&D in support of our Biosimilars portfolio. PATENTS ISSUED TO PFIZER IN 2014 ALONE 131 IN THE U.S. 1,730 OUTSIDE OF THE U.S. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Science > Research...

  • Page 42
    ... gene therapy research and bring forth the next generation of potential life-changing therapies for patients living with serious diseases." KEVIN LEE CHIEF SCIENTIFIC OFFICER RARE DISEASE RESEARCH UNIT PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Science > Research and Development 42

  • Page 43
    ... ALR jointly support novel translational research projects driven by leading academic medical centers within the CTI network. Watch the Focus on Lupus - Pfizer Centers for Therapeutic Innovation (CTI) video PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Science > Research and Development 43

  • Page 44
    ... license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in a potential disease-modifying treatment for Parkinson's disease, which Pfizer has identified as an important area of unmet medical need. This innovative approach to...

  • Page 45
    ... will matter most to the people we serve. As of February 27, 2015 VIEW THE LATEST PIPELINE ON PFIZER.COM Q: HOW DOES PFIZER CHOOSE WHAT MEDICINES TO FOCUS R&D EFFORTS ON? JULIE SCHIFFMAN PORTFOLIO & DECISION ANALYSIS PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Science > Our Pipeline 45

  • Page 46
    ..., from making study participation locations more convenient to using innovative digital tools to collect data and share information." CRAIG LIPSET HEAD OF CLINICAL INNOVATION WITHIN WORLDWIDE RESEARCH & DEVELOPMENT PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Science > Clinical Trials...

  • Page 47
    ... agencies for approved products are also available for researcher use on Pfizer.com. Pfizer's clinical data access policy and the INSPIIRE data request portal are accessible at http://www.pfizer.com/trialdataandresults. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Science > Clinical...

  • Page 48
    ANNUAL REVIEW 2014 LEADING MEDICINES AND VACCINES IMPROVING LIVES THROUGH INNOVATIVE LIFE SCIENCE Pfizer's portfolio includes some of the most widely recognized and well-tested treatments in the world. OUR BEST SELLING MEDICINES AND VACCINES IN 2014 REVENUES FOR PRODUCTS LYRICA (PREGABALIN) ...

  • Page 49
    ... more information on any of these medicines, visit: Pfizer Pharmaceutical Products BREAST CANCER: A STORY HALF TOLD PROTECTING ADOLESCENTS AND YOUNG ADULTS FROM MENINGITIS B READ MORE REDUCING THE RISK OF NVAF-RELATED STROKES READ MORE READ MORE PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual...

  • Page 50
    ... Serogroup B Meningococcal Disease, United States. Advisory Committee on Immunization Practices, October 30, 2014. http://www.cdc.gov/vaccines/acip/meetings/downloads/ slides-2014-10/mening-02-MacNeil.pdf. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Science > Leading Medicines and Vaccines...

  • Page 51
    ANNUAL REVIEW 2014 LEADING MEDICINES AND VACCINES Q: WHAT FACTORS DOES PFIZER CONSIDER WHEN DECIDING THE PRICE OF A MEDICINE? KIRSTEN AXELSEN WORLDWIDE POLICY Q: WHY DO PEOPLE SAY MEDICINES ARE SO EXPENSIVE? JUSTIN MCCARTHY GLOBAL POLICY & INTERNATIONAL PUBLIC AFFAIRS NOTEWORTHY IN OUR ...

  • Page 52
    ... REVIEW 2014 LEADING MEDICINES AND VACCINES QUILLIVANT XR (METHYLPHENIDATE HCL) XALKORI (CRIZOTINIB) XELJANZ (TOFACITINIB) For more information on any of these medicines, visit: Pfizer Pharmaceutical Products PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Science > Leading Medicines...

  • Page 53
    ANNUAL REVIEW 2014 LEADING CONSUMER HEALTHCARE PRODUCTS DELIVERING SCIENCE-BASED SELF-CARE SOLUTIONS Pfizer Consumer Healthcare's products include over-the-counter (OTC) medicines, supplements and other products that are top sellers in their categories and household names for consumers around the...

  • Page 54
    ANNUAL REVIEW 2014 LEADING CONSUMER HEALTHCARE PRODUCTS ADVIL® The No. 1 selling branded OTC analgesic in the world and trusted by millions of consumers for three decades, Advil® is one of Pfizer's billion-dollar brands. In more than 40 countries worldwide, Advil helps consumers treat headaches...

  • Page 55
    ANNUAL REVIEW 2014 LEADING CONSUMER HEALTHCARE PRODUCTS 8 PFIZER CONSUMER HEALTHCARE BRANDS WERE VOTED NUMBER ONE Q: WHAT ROLE DO OVER-THE-COUNTER MEDICINES PLAY IN A PERSON'S LIFE? TROY BENAVIDEZ PFIZER CONSUMER HEALTH IN THEIR RESPECTIVE CATEGORIES, INCLUDING ADVIL, CENTRUM, ROBITUSSIN AND ...

  • Page 56
    ... lips and give them a fuller appearance. In 2014, ChapStick launched three new products: ChapStick Hydration Lock Day & Night, ChapStick Hydration Lock Moisturize & Renew, and Total Hydration. Learn more at chapstick.com EMERGEN-C® A leading health and wellness lifestyle brand, Emergen-C® is...

  • Page 57
    .... Learn more at thermacare.com *These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our Science > Leading Consumer Healthcare Products 57

  • Page 58
    ANNUAL REVIEW 2014 ACCESS TO MEDICINES EXPANDING ACCESS TO ESSENTIAL HEALTH CARE We seek to bring more medicines to more people and to improve health around the world. Our social investments focus on effective and sustainable health care delivery for underserved patients, wherever they live, while...

  • Page 59
    ...in 69 of the world's poorest countries. Sayana Press, a pre-filled, single-use, non-reusable injection, is a re-designed version of an injectable contraceptive from Pfizer's Global Established Pharma's (GEP) women's health portfolio. Created with the target population of women in mind, it eliminates...

  • Page 60
    ... fund designed to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low income countries. For more information please see http://ghif.com/. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our World > Access to Medicines...

  • Page 61
    ... service delivery. Fellows transfer their pharmaceutical and business expertise in ways that promote access, quality and efficiency of health care. In exchange, Fellows return with experience and relationships that help inform their ability to have an impact on pressing health concerns. The Global...

  • Page 62
    ... sites in 63 countries in Africa, Asia, the Caribbean and Latin America. Fifteen years into the program, Pfizer has clearly demonstrated its commitment to addressing public health issues in the developing world by helping improve the quality of life of people living with HIV and AIDS. PFIZER ANNUAL...

  • Page 63
    ... programs, working with nonprofits, advocacy groups, practitioners and community health centers to help fill the gap for people who need help in getting quality health care." RATNA BINDRA DIRECTOR PFIZER RX PATHWAYS PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our World > Access to Medicines...

  • Page 64
    ...discussing these issues, I believe it can help those engaged with Get Old to have an improved patient-physician dialogue. Get Old helps the community be informed, be engaged and be empowered!" WARACHAL EILEEN FAISON, MD GET OLD CONTRIBUTOR PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our World...

  • Page 65
    ANNUAL REVIEW 2014 HEALTHY AGING AGE-FRIENDLY CITIES Pfizer is helping support age-friendly cities in community-based programs across the world. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our World > Healthy Aging 65

  • Page 66
    ... and walkability in areas such as Little Havana in Miami; supporting intergenerational communities in Arizona; helping families and caregivers find services in Kansas City through a new website, linkforcare.org; informing regional planning efforts and advocating for affordable, accessible housing in...

  • Page 67
    ... and support to improve health information management will be undertaken together with the Ministry of Health and Social Welfare at various levels. COMBATING NONCOMMUNICABLE DISEASES WITH INTERGENERATIONAL PROGRAMS IN TANZANIA READ MORE PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our World...

  • Page 68
    ANNUAL REVIEW 2014 PATIENT ENGAGEMENT PATIENTS AT THE CENTER People today are able to access and exchange more information than ever before, and it's no surprise that health is an area where information-sharing is exploding. As patients become more informed, they become more involved - more active...

  • Page 69
    ANNUAL REVIEW 2014 PATIENT ENGAGEMENT PFIZER MEDS APP SICKLE CELL DISEASE CLINICAL TRIAL RECRUITMENT The Pfizer Meds app is designed to provide quick access to information for patients taking Pfizer prescription medicines. By simply scanning or entering the barcode on their prescription medicine...

  • Page 70
    ...with Pfizer medical information offered on the Get Healthy, Stay Healthy website, GetOld.com and social media, connect U.S. audiences with medical expertise, resources and useful tools to help them manage their own and their families' health. Chief Medical Officer, Freda Lewis-Hall, M.D., appeared...

  • Page 71
    ANNUAL REVIEW 2014 ENVIRONMENT WORKING FOR A SUSTAINABLE FUTURE At Pfizer, we recognize that embedding environmental sustainability into our business can bring significant value to our company, the people who use our products and the communities we touch. Building on the successful achievements...

  • Page 72
    .... In 2015, we plan to announce additional targets with the potential to drive meaningful environmental improvements across our supply chain. Our recently revised Climate Change Position Statement can be found here. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our World > Environment 72

  • Page 73
    ... to our customers with innovative, sustainable packaging designs and materials; expanding sustainability efforts across our manufacturing supply chain; and increasing our understanding of our impact on the environment. Our environmental sustainability program complements our focus on developing new...

  • Page 74
    ... on product stewardship, please see here. PHARMACEUTICALS IN THE ENVIRONMENT We are committed to minimizing potential impacts on human health and the environment from the manufacture, use and disposal of our medicines. Pfizer works directly and in partnership with other member companies on trade...

  • Page 75
    ... DISPOSED TOTAL HAZARDOUS AND NON-HAZARDOUS WASTE DISPOSED IN 2014 WAS UNCHANGED FROM 2013. *The API footprint is the same for both tablet sizes; these reductions are specific to the other aspects of the smaller tablet. PFIZER ANNUAL REVIEW 2014 www.pfizer.com/annual Our World > Environment 75